Barclays
VIR icon

Barclays’s Vir Biotechnology VIR Stock Holding History

Barclays’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Sell
116,276
-18,520
-14% -$176K ﹤0.01% 2690
2026
Q1 		$1.21M Sell
134,796
-231,030
-63% -$1.84M ﹤0.01% 2637
2025
Q4 		$2.21M Sell
365,826
-44,580
-11% -$265K ﹤0.01% 2864
2025
Q3 		$2.34M Sell
410,406
-63,252
-13% -$323K ﹤0.01% 2771
2025
Q2 		$2.39M Buy
473,658
+262,035
+124% +$1.4M ﹤0.01% 2712
2025
Q1 		$1.37M Sell
211,623
-9,555
-4% -$85K ﹤0.01% 2920
2024
Q4 		$1.62M Sell
221,178
-329,008
-60% -$2.6M ﹤0.01% 3055
2024
Q3 		$4.12M Buy
550,186
+7,287
+1% +$63.3K ﹤0.01% 2256
2024
Q2 		$4.83M Sell
542,899
-471,780
-46% -$4.52M ﹤0.01% 1561
2024
Q1 		$10.3M Buy
1,014,679
+569,985
+128% +$5.8M ﹤0.01% 1370
2023
Q4 		$4.47M Buy
444,694
+32,533
+8% +$297K ﹤0.01% 2192
2023
Q3 		$3.86M Buy
412,161
+228,634
+125% +$3.26M ﹤0.01% 1492
2023
Q2 		$4.5M Sell
183,527
-48,975
-21% -$1.23M ﹤0.01% 1413
2023
Q1 		$5.41M Buy
232,502
+36,277
+18% +$928K ﹤0.01% 1483
2022
Q4 		$4.97M Sell
196,225
-43,263
-18% -$1.06M ﹤0.01% 1639
2022
Q3 		$4.62M Buy
239,488
+210,711
+732% +$5.36M 0.01% 1217
2022
Q2 		$734K Sell
28,777
-72,114
-71% -$1.68M ﹤0.01% 2577
2022
Q1 		$2.6M Buy
+100,891
New +$2.99M ﹤0.01% 1668

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Barclays's VIR Position: Q2 2026 in Review

Barclays reduced its Vir Biotechnology (VIR) stake by 14% in Q2 2026, selling an estimated $176K and leaving 116,276 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2690.

Barclays first reported a position in VIR in Q1 2022 and has held it in 18 quarters since. The position peaked at $10.3M in Q1 2024. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Barclays held 116,276 shares of Vir Biotechnology worth $1.18M as of Q2 2026.
  • Barclays sold 18,520 Vir Biotechnology shares in Q2 2026, an estimated $176K.
  • Vir Biotechnology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2690 holding.
  • Barclays first reported a position in Vir Biotechnology in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Vir Biotechnology position peaked at $10.3M in Q1 2024.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.